EQRx (Nasdaq: EQRX or EQRXW) is a first-of-a-kind company that is revolutionizing the way medicines are discovered, developed, and brought to people.
eqrx.com
Cambridge, MA
CEO: Alexis Borisy
Arboretum Lead: Jan Garfinkle
EQRx
IN THE NEWS
EQRx Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Progress
EQRx Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Progress
Read More
EQRx Announces Acceptance of Marketing Authorization Application by the European Medicines Agency
Application is based on data from the pivotal Phase 3 AENEAS trial evaluating aumolertinib as first-line treatment of patients with EGFR-mutated non-small cell lung cancer.
Read More
EQRx Reports Second Quarter 2022 Financial Results and Recent Corporate Progress
EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at radically lower prices, today reported financial results for the second quarter…
Read More
EQRx Announces Acceptance of Market Authorization Application by the UK’s MHRA
EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at radically lower prices, today announced that the United Kingdom (U.K.)’s Medicines…
Read More
